Clinical Trial Update: Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases

View source ↗

Summary

This entry describes a real-world study of Taletrectinib for advanced ROS1-positive non-small cell lung cancer with brain metastases, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Taletrectinib (taletrectinib)

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Non-Small Cell Lung Cancer | Status: RECRUITING